Supported by independent educational grants from Neurocrine Biosciences and Teva Pharmaceuticals.

Claim CPNP Webinar Credit Here
If you participated in the College of Psychiatric and Neurologic Pharmacists (CPNP) virtual program and are looking to claim credit, click on the headline above.
Tardive Dyskinesia Improvement Sustained With Long-term Valbenazine
Once-daily valbenazine was effective and generally well tolerated in adults with tardive dyskinesia who took the drug for up to 48 weeks, according to a study published online in The Journal of Clinical Psychiatry.
Strategies for Detecting and Treating Tardive Dyskinesia
The availability of new drugs for tardive dyskinesia (TD) means clinicians have an increased responsibility to proactively screen for the disorder and treat it when detected, Psych Congress cochair Rakesh Jain, MD, MPH, said.
Researchers Develop New Scale to Assess Tardive Dyskinesia Effects
Researchers have developed a new scale to measure the impacts tardive dyskinesia has on patients and their caregivers, according to a poster abstract presented at Psych Congress 2017.
FDA Approves Deutetrabenazine for Treatment of Tardive Dyskinesia
The US Food and Drug Administration has approved deutetrabenazine for the treatment of tardive dyskinesia in adults, Teva Pharmaceutical Industries announced.
Tardive Dyskinesia Linked With Medical Comorbidity in Veterans
SAN FRANCISCO—Tardive dyskinesia (TD) is strongly linked with older age, medical comorbidity, and hospitalizations, according to a study of US veterans with serious mental illness presented during a poster session at the American Psychiatric Association’s annual meeting.
In-depth Discussion about Deutetrabenazine and Valbenazine
Drs. Jain and Kumar provide and in-depth analysis of two new VMAT2 inhibitors approved to treat tardive dyskinesia.
Can Dual Treatments Be Used for Tardive Dyskinesia?
Is there any rationale for using both deutetrabenazine (Austedo) and valbenazine (Ingrezza) at the same time? Find out from Psych Congress cochair Rakesh Jain, MD, MPH.
Treating Patients With Long-term Tardive Dyskinesia
Is there benefit in treating a patient with a VMAT2 inhibitor if they have already had severe tardive dyskinesia for several years? Find out here.
Does Tardive Dyskinesia Severity Impact the Effectiveness of Treatments?
Are medications for tardive dyskinesia effective in mild, moderate, or severe cases? Get the answer from Psych Congress cochair Rakesh Jain, MD, MPH.
Trunk (neck, shoulders, hips)
e.g. rocking, twisting, squirming, pelvic gyrations More Videos
Back to Top